Downregulation of T-cell cytotoxic marker IL18R1 promotes cancer proliferation and migration and is associated with dismal prognosis and immunity in lung squamous cell carcinoma

• Published in: Frontiers in immunology Vol. 13; p. 986447
• Main Authors: Guo, Qiang, Wu, Chuang-Yan, Jiang, Ni, Tong, Song, Wan, Jun-Hao, Xiao, Xiao-Yue, Mei, Pei-Yuan, Liu, Hua-Song, Wang, Si-Hua
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 05.12.2022
• Subjects: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; CD3 Complex; Cell Proliferation; Down-Regulation; Humans; immune microenvironment; Immunology; interleukin 18 receptor 1; Interleukin-18 Receptor alpha Subunit; Lung; Lung Neoplasms - genetics; lung squamous cell carcinoma; MicroRNAs - genetics; Prognosis; T cytotoxic cells; Tumor Microenvironment; T cytotoxic cells; interleukin 18 receptor 1; immune microenvironment; prognosis; lung squamous cell carcinoma
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.986447

Immunotherapy can improve the survival of patients with advanced lung squamous cell carcinoma (LUSC). T cytotoxic cells are one of the main members of the immune microenvironment. Herein, we aimed to identify the roles of T-cell cytotoxic markers interleukin 18 (IL18) receptor 1 (IL18R1) in the LUSC progression using bioinformatics, clinical tissue specimen, and cell experiment. We assessed the association between the IL18R1 expression and immune infiltration and IL18R1-related competing RNA network. The IL18R1 expression was downregulated in the LUSC tissues. The IL18R1 expression downregulation was associated with diagnosis and short overall survival and disease-specific survival, and it was also an independent risk factor for dismal survival time in LUSC. IL18R1-related nomograms predicted the survival time of patients with LUSC. IL18R1 overexpression inhibited the proliferation, migration, and invasion of LUSC cells. The IL18R1 expression was significantly associated with the microenvironment (stromal, immune, and estimate scores), immune cells (such as the T cells, cytotoxic cells, CD8 T cells), and immune cell markers (such as the CD8A, PD-1, and CTLA4) in LUSC. AC091563.1 and RBPMS-AS1 downregulation was positively associated with the IL18R1 expression, negatively associated with the miR-128-3p expression, and associated with short disease-specific survival and progression in LUSC. In conclusion, IL18R1 was significantly downregulated and associated with the prognosis and immune microenvironment. IL18R1 overexpression inhibits the growth and migration of cancer cells in LUSC. Furthermore, AC091563.1 and RBPMS-AS1 might compete with IL18R1 to bind miR-128-3p for participating in LUSC progression. These results showed that IL18R1 is a biomarker for evaluating the prognosis of patients with LUSC.